Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Clin Immunol. 2014 Apr 8;34(4):428–435. doi: 10.1007/s10875-014-0028-1

Figure 4.

Figure 4

Immunoglobulin replacement dosing. A) The interval between doses is shown for both XLA and common variable immune deficiency, dividing entries according to intravenous (IV) or subcutaneous (SC) entries. B) The monthly dose is shown for XLA and common variable immune deficiency, according to subcutaneous (SC) or intravenous (IV) administration.